ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 587,90
-0,59%
Dow Jones
40 211,72
0,53%
DAX
18 519,75
-0,43%
Brent Oil
83,66
-0,81%
Bitcoin
63 191,82
-2,56%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
10/05/201122h00Business WireAllos Therapeutics Reports First Quarter 2011 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/05/201120h42ZacksMixed Results for CELG's Revlimid - Analyst BlogNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/05/201114h00Business WireAllos Therapeutics to Present at Upcoming Investor Conferences in MayNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/05/201114h00Business WireAllos Therapeutics to Report First Quarter 2011 Results on May 10, 2011NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/05/201114h16MarketwiredOncology Drug Makers Positioned for Long Term GrowthNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/04/201122h48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/04/201118h35Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (DEFA14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/04/201118h31Edgar (US Regulatory)Proxy Statement (definitive) (DEF 14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/04/201119h01ZacksAllos Therapeutics at Neutral - Analyst BlogNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/04/201117h20ZacksCancer Study to Continue at SPPI - Analyst BlogNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/03/201114h00Business WireAllos Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/03/201112h35MarketwiredSpeculative Biotech Firms Remain Popular Takeover TargetsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/03/201122h27Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/201122h20Edgar (US Regulatory)Annual Report (10-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/201122h00Business WireAllos Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of FOLOTYN in Patients with Pre...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/201122h00Business WireAllos Therapeutics Reports Fourth Quarter and Full Year 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/02/201115h00Business WireAllos Therapeutics to Report Fourth Quarter and Full Year 2010 Results on March 3, 2011NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
14/02/201122h40Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/02/201120h37Edgar (US Regulatory)Statement of Ownership (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/01/201100h31Business WireJournal of Clinical Oncology Publishes Results from Pivotal Phase 2 PROPEL Study of FOLOTYN® in Relapsed or Refractory Perip...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/01/201114h00Business WireAllos Therapeutics Reports 2010 Financial Highlights and 2011 Key Business PrioritiesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
21/12/201014h00Business WireAllos Therapeutics’ Marketing Authorisation Application (MAA) for FOLOTYN® Accepted for Review by European Medicines Agenc...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/12/201014h00Business WireAllos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/12/201021h15Business WireNew Analysis from Phase 2b Study Reinforces Favorable Survival Data Observed with FOLOTYN® Relative to Erlotinib in Advanced...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/12/201015h00Business WireUpdated Results from FOLOTYN® Phase 1 Dose Finding Study Demonstrates Activity in Relapsed or Refractory Cutaneous T-Cell Ly...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/201015h00Business WireAllos Therapeutics Reports New Analyses of FOLOTYN® Data from PROPEL trial in Relapsed or Refractory Peripheral T-Cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/201015h00Business WireNew Analysis from FOLOTYN® PROPEL Trial Demonstrates Activity in Relapsed or Refractory Transformed Mycosis FungoidesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/12/201014h00Business WireAllos Therapeutics Announces FOLOTYN® Data to Be Presented as a Late Breaker at the 2010 Chicago Multidisciplinary Symposium...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/11/201014h00Business WireNew FOLOTYN® Data to Be Presented at the 2010 American Society of Hematology Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/11/201021h10Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

EU
AI
Air Liquide
NASDAQ
AAPL
Apple
EU
PX1
CAC 40
EU
VIV
Vivendi
EU
BNP
BNP Paribas
NASDAQ
GOOGL
Alphabet
FTSE
UKX
FTSE 100
COIN
BTCUSD
Bitcoin
NYSE
NKE
Nike
EU
HO
Thales
EU
AF
Air FranceKLM
EU
PX4
SBF 120
EU
EN
Bouygues
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés